Heart Protection in Rheumatoid Arthritis With New Medications
Treatments studied
Part of Bones, joints & muscles, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study compares two treatment approaches for people with active rheumatoid arthritis who also have heart disease risk factors. It tests whether a newer drug called tofacitinib, combined with cholesterol medication, can better protect the heart than traditional TNF-inhibitor treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rheumatoid arthritis (RA) that is moderate to severe despite taking at least 2 traditional RA medications
- You are 50 years old or older
- You have at least one heart disease risk factor, such as high blood pressure, diabetes, smoking history, or high cholesterol
- You are not allergic or unable to take statin medications (cholesterol-lowering drugs)
- You have not had a recent heart attack or stroke
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This trial looks at cardiovascular risk factors in people with rheumatoid arthritis (RA), comparing those who test positive or negative for certain blood markers. It aims to understand how heart health may differ between these groups.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This study uses a special heart CT scan to look for early signs of heart disease in people with rheumatoid arthritis. It may help find problems before symptoms start.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.